AXIOS November 19, 2024
Maya Goldman

Between Robert F. Kennedy Jr. and Vivek Ramaswamy, the incoming Trump administration has divergent views on regulating the pharmaceutical industry.

Why it matters: Both influential MAGA allies say there are deep problems with America’s drug development system. But RFK Jr., the Health and Human Services secretary designee, is calling for more oversight of drugs and vaccines and diminished federal funding for R&D.

  • Ramaswamy, a biotech entrepreneur who will lead a new “Department of Government Efficiency” with Elon Musk, is a small government aficionado who’s called for fewer barriers to bringing drugs to market.

Their differences add another layer of uncertainty for pharmaceutical companies trying to navigate what could be dizzying changes in the new administration.

Where it stands:...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Pharma, Pharma / Biotech, Regulations
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug

Share This Article